O1-1-5 - Role of Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients with Aml or High Risk Mds

Abstract

Background: Hematologic malignancies are more common among older patients. This age group has historically had worse outcomes when compared with younger counterparts. Allogeneic hematopoietic stem cell transplantation (HSCT) can achieve durable remissions in a number of patients with advanced hematologic malignancies, but its application to the elderly has been traditionally limited by arbitarry age restrictions, reflecting concerns of high rates of nonrelapse mortality and morbidity. Although the advent of reduced intensity conditioning regimens has extended HSCT to increasingly older adoults, little is knowm about the role of HSCT in practice.Patients: Consecutive patients age 60 or older (N = 31, 61-87) administered in our hospital between 2012 to 2013. Diseases included AML and MDS overt leukemia (N = 21,20). Nineteen patients were explained about HSCT (age: 61-77), and nine of them (age: 61-69) underwent HSCT.Result: The one year overall survivals were 42% (all patients), 60% (age:60-69), 11% (age:over 70) respectively/ In the patients age between 60 to 70, almost of patients reqested for HSCT, the patients whi underwent HSCT had a better one year overall survivals (78%) compared with who did not underdo HSCT (excluded patients who had good risk karyotype).Conclusion: Allogeneic HSCT i an effective option for carefully selected patients age 60 or older in practice.